Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Melanoma 4Multiple Myeloma 2Uveal Melanoma 1Skin Neoplasms 1Neoplasms, Plasma Cell 1Neoplasms 1Neoplasm Metastasis 1Eye Neoplasms 1

Interventions

Dexamethasone 32Cyclophosphamide 30fludarabine phosphate 25Melphalan 25Busulfan 25Bortezomib 21Tacrolimus 20Lenalidomide 19Peripheral Blood Stem Cell Transplantation 18Mycophenolic Acid 17Whole-Body Irradiation 16Antilymphocyte Serum 16fludarabine 14Calcium Dobesilate 13Thalidomide 12Filgrastim 12Granulocyte Colony-Stimulating Factor 11Methotrexate 10pomalidomide 9Cyclosporine 8Radiotherapy 6Etoposide 6Cord Blood Stem Cell Transplantation 6Surveys and Questionnaires 5Stem Cell Transplantation 5Rituximab 5Methylprednisolone 5sargramostim 4carfilzomib 4Sirolimus 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Neoplasms, Plasma Cell × MAGEA3 protein, human × Clear all
NCT00090493 2013-06-24

Study of MAGE-A3 and NY-ESO-1 Immunotherapy in Combo With DTPACE Chemo and Auto Transplantation in Multiple Myeloma

University of Arkansas

Phase 2/3 Completed
4 enrolled 6 charts
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡